Cur­tain-rais­er da­ta keep an­a­lysts on edge ahead of Am­gen’s big Lumakras/PD-1 com­bo read­out

Will a com­bi­na­tion reg­i­men bring Am­gen’s big KRAS drug to new heights?

That’s the ma­jor ques­tion Wall Street found it­self mulling in the wake of an ab­stract drop from the an­nu­al World Con­fer­ence on Lung Can­cer. While there were some ear­ly da­ta avail­able on Am­gen’s Lumakras plus a SHP2 in­hibitor be­ing de­vel­oped by Sanofi and Rev­o­lu­tion Med­i­cines, the key read­out — from a study pair­ing Lumakras with a PD-1 drug — is be­ing held back for a late-break­er in Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER